Cutler Group’s Milestone Pharmaceuticals MIST Stock Holding History

Cutler Group’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,500	Closed	-$2K	–	4901
2022 Q3	$2K	Buy	+2,500	New	+$19K	﹤0.01%	4244

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's MIST Position: Q1 2023 in Review

Cutler Group sold out of Milestone Pharmaceuticals (MIST) in Q1 2023, closing a stake of 600 shares — an estimated $2K sold.

Cutler Group first reported a position in MIST in Q3 2022 and held it in 2 quarters. The position peaked at $36K in Q3 2022. 50 funds tracked by Wall St. Rank hold MIST as of Q1 2023.

Cutler Group reported no remaining Milestone Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 600 Milestone Pharmaceuticals shares in Q1 2023, an estimated $2K.
Cutler Group first reported a position in Milestone Pharmaceuticals in Q3 2022 and held it in 2 quarters.
Cutler Group's Milestone Pharmaceuticals position peaked at $36K in Q3 2022.
50 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.